NEST-1: Neoadjuvant Botensilimab, Balstilimab for pMMR/MSS Colorectal Cancer
By Pashtoon Kasi, MD, MS - Last Updated: March 19, 2025Pashtoon Kasi, MD, MS, Weill Cornell Medicine, showcases the NEST-1 clinical trial, an early-stage investigation into neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer.
Advertisement
Dr. Kasi expounds on what the latest data shows regarding adverse events and downstaging as a result of this regimen.
View Dr. Kasi’s other comments on BESPOKE CRC: ctDNA for Informing Adjuvant Chemotherapy in Colorectal Cancer.
All images and data were presented at the 2024 American Society of Clinical Oncology® Gastrointestinal Cancer Symposium.
Advertisement
Related Posts
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
Experts speak on the new face of CRC, the potential mechanisms for these trends, and how CRC screening programs should react.
Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.
Dr. James Cleary discusses the use of HER2-directed therapies for the treatment of CRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.